Psoriatic Arthritis Research Collaborative: Biologic Sub-Study



Status:Recruiting
Conditions:Arthritis, Psoriasis
Therapuetic Areas:Dermatology / Plastic Surgery, Rheumatology
Healthy:No
Age Range:18 - 89
Updated:2/9/2019
Start Date:December 31, 2017
End Date:January 1, 2020
Contact:Kathleen Bush, BS
Email:katbu@upenn.edu
Phone:215-662-6332

Use our guide to learn which trials are right for you!

Psoriatic arthritis (PsA) is an inflammatory arthritis with substantial variation in clinical
features. We propose a multicenter collaborative approach to better understand the phenotypes
and current management of PsA in the United States.The central goal of this proposal is to
obtain the data necessary to design a pragmatic trial in PsA.

Psoriatic arthritis (PsA) is a chronic inflammatory arthritis that can be associated with
devastating outcomes including irreversible joint damage. The management of a patient with
PsA is extremely challenging due to the high degree of phenotypic heterogeneity. The ultimate
goal of this proposal is to prepare pragmatic trials in PsA trials that will encompass all
relevant subgroups of patients. The aims of this study specifically focus on responses to
biologic therapy among patients with PsA and determining the optimal set of outcome measures
for PsA trials.

Inclusion Criteria:

- Age 18-89

- Active PsA (at least one swollen joint or enthesitis) -Meet CASPAR criteria (Table 2)
(103) -Initiation of TNFi (etanercept, adalimumab, infliximab, certolizumab,
golimumab) (At the time of the submission, TNFi biosimilars have been approved by the
FDA but are not available on the US market. Once available, patients starting TNFi
biosimilars will similarly be eligible for participation. Patients may have been on
the medication in the past but must have had greater than 2 months off the
medication.Patients may be taking other traditional DMARDs. A washout period is not
required.)

Exclusion Criteria:

- Unable to give informed consent

- Out of the age range

- Switching therapies for skin psoriasis in the setting of well controlled joint and
enthesis symptoms.

- Patients with only active PsA
We found this trial at
4
sites
New York, New York 10016
Principal Investigator: Soumya Reddy, MD
Phone: 646-501-7400
?
mi
from
New York, NY
Click here to add this to my saved trials
9500 Euclid Avenue
Cleveland, Ohio 44106
216.444.2200
Phone: 216-445-1953
Cleveland Clinic Cleveland Clinic is committed to principles as presented in the United Nations Global...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
3400 Spruce St
Philadelphia, Pennsylvania 19104
 (215) 662-4000
Principal Investigator: Alexis Ogdie-Beatty, MD, MSCE
Phone: 215-662-6332
Hospital of the University of Pennsylvania The Hospital of the University of Pennsylvania (HUP) is...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
201 Presidents Circle
Salt Lake City, Utah 84108
801) 581-7200
Phone: 801-581-7724
University of Utah Research is a major component in the life of the U benefiting...
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials